%0 Journal Article
%A Placke, Jan-Malte
%A Kimmig, Mona
%A Griewank, Klaus
%A Herbst, Rudolf
%A Terheyden, Patrick
%A Utikal, Jochen
%A Pföhler, Claudia
%A Ulrich, Jens
%A Kreuter, Alexander
%A Mohr, Peter
%A Gutzmer, Ralf
%A Meier, Friedegund
%A Dippel, Edgar
%A Welzel, Julia
%A Engel, Daniel Robert
%A Kreft, Sophia
%A Sucker, Antje
%A Lodde, Georg
%A Krefting, Frederik
%A Stoffels, Ingo
%A Klode, Joachim
%A Roesch, Alexander
%A Zimmer, Lisa
%A Livingstone, Elisabeth
%A Hadaschik, Eva
%A Becker, Jürgen
%A Weichenthal, Michael
%A Tasdogan, Alpaslan
%A Schadendorf, Dirk
%A Ugurel, Selma
%T Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM.
%J EBioMedicine
%V 96
%@ 2352-3964
%C Amsterdam [u.a.]
%I Elsevier
%M DKFZ-2023-01806
%P 104774
%D 2023
%X PD-1-based immune checkpoint inhibition (ICI) is the major backbone of current melanoma therapy. Tumor PD-L1 expression represents one of few biomarkers predicting ICI therapy outcome. The objective of the present study was to systematically investigate whether the type of tumor tissue examined for PD-L1 expression has an impact on the correlation with ICI therapy outcome.Pre-treatment tumor tissue was collected within the prospective DeCOG cohort study ADOREG/TRIM (CA209-578; NCT05750511) between February 2014 and May 2020 from 448 consecutive patients who received PD-1-based ICI for non-resectable metastatic melanoma. The primary study endpoint was best overall response (BOR), secondary endpoints were progression-free (PFS) and overall survival (OS). All endpoints were correlated with tumor PD-L1 expression (quantified with clone 28-8; cutoff ≥5
%K Biomarker (Other)
%K Immune checkpoint inhibition (Other)
%K Melanoma (Other)
%K Therapy outcome (Other)
%K Tumor PD-L1 (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37660535
%R 10.1016/j.ebiom.2023.104774
%U https://inrepo02.dkfz.de/record/282517